SUBSCRIBE: RSS Feed for Spinal Cord Injury Zone Email Updates Follow Spinal Cord Injury Zone on Twitter Spinal Cord Injury Zone on Facebook

Browsing Articles by Date

Reflections on the 50th Anniversary of Joni’s Diving Accident

Published: July 30, 2017 | Category: News | Spinal Cord Injury: ,

Recently I was at my desk writing to Tommy, a 17-year-old boy who just broke his neck body surfing off the Jersey shore. He’s now a quadriplegic. He will live the rest of his life in a wheelchair without use of his hands or legs. When it comes to life-altering injuries, quadriplegia is catastrophic.

Halfway through my letter describing several hurdles Tommy should expect in rehab, I stopped. I felt utterly overwhelmed, thinking of all that lies ahead for him. I’ve been there. And even though half a century has passed, I can still taste the anguish. Hot, silent tears began streaming, and I choked out a prayer, Oh God, how will Tommy do it? How will he ever make it? Have mercy; help him find you!  Continue Reading »

App helps drivers in wheelchairs get help at the gas pump

Published: July 28, 2017 | Category: News

Langley’s Zosia Ettenberg says refuelling in wheelchair impossible without assistance

The simple act of filling a gas tank can be an insurmountable challenge for people who use a wheelchair.

That was the experience of Langley resident Zosia Ettenberg.

“It’s literally impossible for me to pump gas by myself,” Ettenberg told On the Coast host Tanya Fletcher.

“I have to park far enough away from the gas pump to get out, and then go around and have enough space for the wheelchair between the car and the pump,” Ettenberg said. Continue Reading »

Q Therapeutics Approved to Start Trial of Cell Therapy Aiming to Restore Myelin

Published: July 26, 2017 | Category: News

A cell therapy intended to boost myelin regeneration — Q-Cells by Q Therapeutics — has received a green light from the U.S. Food and Drug Administration to proceed with a clinical trial in patients with transverse myelitis (TM), a disease that like multiple sclerosis is characterized by myelin damage.

FDA approval of the company’s Investigational New Drug (IND) application allows researchers to start a Phase 1/2 clinical trial in which nine patients will receive increasing doses of the treatment. Continue Reading »

Hard-knock life? Performance of “Annie” by cast with disabilities adds heft, power to classic story

Published: July 25, 2017 | Category: News

The Colorado-based Phamaly Theatre Company has burnished its artistic reputation by selecting shows that resonate — intellectually and emotionally — with the many facets of disability. Cast entirely with performers who live with disabilities, the shows engage questions of possibility and perseverance as well as marginalization and discrimination.

Just as vitally, they take theater seriously, they entertain. Although it has expanded its yearly offerings, the company continues to produce a winter play and a summer musical. Even a musical as non-taxing and agreeable as its current one, “Annie,” offers fresh and telling insights. Continue Reading »

Drug aims to help treat spinal cord injuries

Published: July 25, 2017 | Category: News

Researchers at ReNetX Bio are hoping a new name, the potential for a new influx of cash on the horizon and a new chief executive officer are the winning combination needed to bring its lead drug candidate to market.

ReNetX Bio is looking to guide its drug candidate, Nogo Trap, through its first round of clinical trials. Company officials say Nogo Trap is designed to help patients with chronic spinal cord injury. Continue Reading »

8-year-old boy raises money to buy his bestie a new wheelchair

Published: July 24, 2017 | Category: News | Spinal Cord Injury: ,

When Paul Burnett first met Kamden Houshan in kindergarten, the two boys quickly became friends. They bonded over playing superheroes and creating goofy videos. While others often focus on Kamden’s wheelchair and disability, Paul never acted like Kamden was different.

“What really contributes to their friendship is that Paul does not see Kamden as someone who has a disability. He sees him as Kamden. Because of that Kam truly is himself around him,” Yvonne Houshan, Kamden’s mom, told TODAY.

Continue Reading »

New wheelchair provides opportunities for quadriplegic hunter

Published: July 18, 2017 | Category: News | Spinal Cord Injury: ,

The nonprofit Independence Fund gave Nels Hadden an all-terrain wheelchair Tuesday.

Nels Hadden may not be able to move his arms or legs, but he can still take down a deer with a crossbow.

There’s no magic spell or use of the Force, just the power of technology that lets quadriplegic men and women do things that would have been impossible years ago. Continue Reading »

Iowa Boy’s Inspirational Showing Draws A Standing Ovation At The National Junior Angus Show

Published: July 15, 2017 | Category: News | Spinal Cord Injury:

Alec Gotto was just a few weeks old when he was diagnosed with transverse myelitis, a syndrome that causes spine inflamation and makes movement of the legs and arms extremely difficult.

The young boy from the small town (and my hometown) of Dyersville, Iowa didn’t let it slow him down.

With his boots tucked into the straps of his motorized wheelchair, he got the crowd out of their own seats and up on their feet as he proudly showed his steer at the National Junior Angus Show in Des Moines. Continue Reading »

About Spinal Cord Injury

Published: July 13, 2017 | Category: Featured Information

Anna Hopson’s PowerPoint presentation and interactive online lesson about spinal cord injury. Anna covers everything related to spinal cord injuries in this 35 minute Microsoft Office Mix Presentation.

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Published: July 10, 2017 | Category: News | Spinal Cord Injury:

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials

FREMONT, Calif., July 10, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s amendment to the clinical research protocol for its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in motor complete cervical spinal cord injury (SCI). The amendment expands the eligibility criteria to include patients with a C-4 spinal cord injury and extends the dosing window from 14 to 30 days to 21 to 42 days post-injury. Continue Reading »